Related Experiment Videos
Epirubicin and DTIC (EDIC) for advanced soft-tissue sarcomas
M Lopez1, S Carpano, L Di Lauro
1Department of Medical Oncology II, Regina Elena Institute for Cancer Research, Rome, Italy.
Oncology
|January 1, 1991
Summary
This study shows epirubicin combined with DTIC is effective for advanced soft-tissue sarcomas, offering a promising treatment option with manageable side effects and reduced cardiac toxicity compared to similar drugs.
Area of Science:
- Medical Oncology
- Pharmacology
Background:
- Soft-tissue sarcomas are rare cancers.
- Current treatments have limitations, including cardiotoxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of epirubicin plus DTIC in advanced soft-tissue sarcomas.
- To assess the cardiotoxicity profile of this combination regimen.
Main Methods:
- A phase II clinical trial was conducted.
- Fifty-six patients with advanced soft-tissue sarcomas received epirubicin and DTIC every 3 weeks.
- Response rates and toxicity, including cardiac function (left-ventricular ejection fraction - LVEF), were monitored.
Main Results:
- An overall response rate of 48% was observed in 52 evaluable patients, including 9 complete remissions.
- Non-cardiac toxicities included vomiting, alopecia, and myelosuppression.
- Laboratory evidence of cardiotoxicity (LVEF decrease) occurred in 4/39 patients; clinical congestive heart failure in 2 patients at higher cumulative doses.
Conclusions:
- The epirubicin and DTIC combination is an active and effective regimen for advanced soft-tissue sarcomas.
- Epirubicin demonstrates efficacy similar to doxorubicin but with potentially reduced cardiac toxicity.